Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott Antonia(Moffitt Cancer Center), Hossein Borghaei(Fox Chase Cancer Center), Suresh S. Ramalingam(Emory University), Leora Horn(Vanderbilt University Medical Center), Javier de Castro(Centro Oncológico de Galicia), Adam Płużański(Centrum Onkologii), Marco Angelo Burgio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marina Chiara Garassino(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Q.M. Chow(University of Washington Medical Center), Scott Gettinger(Yale Cancer Center), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), David Planchard(Institut Gustave Roussy), Charles Butts, Alexander Drilon(Memorial Sloan Kettering Cancer Center), Joanna Wójcik-Tomaszewska(Centrum Onkologii), Gregory A. Otterson(The Ohio State University), Shruti Agrawal(Bristol-Myers Squibb (United States)), Ang Li(Bristol-Myers Squibb (United States)), John R. Penrod(Bristol-Myers Squibb (United States)), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center)
The Lancet Oncology
August 14, 2019
Cited by 365Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis